The knockdown of METTL3 in pancreatic cancer cell lines increases the sensitivity of the cells to gemcitabine, cisplatin and other drugs, even though the morphology and proliferative abilities of the cells did not change, providing a new potential target for the treatment of pancreatic cancer. The gene discussed is METTL3; the disease is pancreatic neoplasm.